COLLABORATIVE ARRANGEMENTS (Details 7) (Commercialization Agreement, Hikma Pharmaceuticals LLC, Telavancin, USD $) In Millions, unless otherwise specified	1 Months Ended
	Jun. 30, 2013	May 30, 2013	May 31, 2013 Item	Sep. 30, 2013 Maximum
Information related to collaborative arrangements
Number of countries across MENA in which commercialization rights were granted			16
Upfront payment	$ 0.5
Potential future contingent payments receivable				$ 0.5
Agreement term		15 years